ERG and prostate carcinoma: ERG gene rearrangements and ERG expression have been documented in roughly 50% of localized prostate and locally advanced castrate resistant prostate cancer compared to 12%–15% in watchful waiting or incidental cohorts [16, 17, 22, 25, 29].